News Hub | News Direct

News Release

The Bermuda Business Development Agency (BDA) Enters New Era as Investment Promotion Agency and Appoints Managing Director

BDA Bermuda

The Bermuda Business Development Agency (BDA) is taking a bold step forward in its mission to attract high-value Foreign Direct Investment (FDI) with the launch of an Investment Promotion Agency (IPA) model. This transformation focuses on delivering measurable economic outcomes — creating jobs, driving business incorporations, and strengthening Bermuda’s position as a premier global investment destination. Leading this evolution is Managing Director, Kendaree Burgess. The IPA model represents a significant shift in how the BDA will engage with potential investors, anchoring its efforts in results and data-driven strategies. By focusing on key metrics such as business incorporations, long-term investments, and the growth of enterprises on the island, the BDA is positioning Bermuda as a premier investment jurisdiction. A career executive with over 25 years’ experience across a broad range of sectors including financial services, hospitality, and healthcare, Burgess joined the BDA in March 2023, as Chief Operating Officer. Leading efforts to streamline operations, optimise systems, enhance efficiency, and improve organisational performance, she also spearheaded the transition to an IPA, setting a clear path towards successful implementation. Prior to joining the BDA, Ms. Burgess was CEO of the Bermuda Chamber of Commerce where she not only focused on economic development, public policy, and fiscal responsibility, but also helped drive legislative changes to benefit industry, and Bermuda’s future economic development. The BDA has bolstered its leadership team to drive the new strategy. Industry veterans, David Parker, Head of Business Development, and Simone Gibbons, Head of Marketing, Communications & Events, are tasked with driving targeted market engagement and brand positioning. Together, they will work alongside sector-specific business development managers and research and intelligence specialists to implement a strategy that identifies meaningful investment opportunities, builds lasting partnerships, and ensures Bermuda achieves sustained economic growth. Olivia Joell has been promoted to the role of Stakeholder Relationship Manager, a new position created to deepen engagement with local industry and encourage reinvestment in Bermuda. Recognising that a significant portion of FDI globally comes from reinvestment by companies already operating on the ground, this role is essential to fostering long-term partnerships and helping local and international businesses see continued opportunities for growth and success. Together, this diverse group is equipped to deliver on the promise of the IPA model by prioritising actionable, measurable outcomes that create lasting benefits for Bermuda. Ms. Burgess said, “The transition to an IPA model redirects our focus to attracting Foreign Direct Investment that leverages Bermuda’s unique strengths and supports our economic goals. The BDA will prioritise sectors with the highest potential to diversify the economy, boost GDP, and advance key components of the government’s economic development strategy. “This year marks a significant milestone in the BDA’s evolution. The IPA model is not just about strategy; it’s about delivering measurable, meaningful outcomes for Bermuda’s economy — things that matter to ordinary Bermuda residents, such as expanding opportunities across diverse industries. Over the next six months, we will focus on engaging with industry leaders and building partnerships that position Bermuda as a leader in global investment. This has been a pivotal shift in the BDA’s transformation. The resilience and adaptability of our team have been remarkable, and I look forward to engaging with stakeholders to unlock opportunities that will shape Bermuda’s economic future. “Bermuda can expect clear evidence of the IPA model’s effectiveness through transparent reporting and concrete results. By prioritising outcomes that benefit everyday residents, we will demonstrate its success and impact on the island.” Susan Pateras, BDA Board member, added, “The adoption of the IPA model is a bold and forward-looking step that equips us to meet the evolving needs of investors. None of this would have been possible without the support of our government and our industry partners. Under Kendaree Burgess’s leadership, the BDA is well-positioned to achieve tangible economic growth. Successful investment promotion requires a collaborative effort, and we are committed to working closely with Government and local stakeholders to create an environment where businesses can thrive.” Media Contact: Nadia Hall PR & Communications Manager M. +1 441 747 5269 E: nadia@bda.bm Contact Details Melvin Dickinson Melvin@bda.bm

February 05, 2025 09:26 AM Eastern Standard Time

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance

Benzinga

By Meg Flippin Benzinga It is often said that, “Prostate cancer is the cancer you die with, not because of,” but according to RedHill Biopharma (NASDAQ: RDHL), based on data published in Frontiers in Public Health, around 400,000 men a year worldwide would probably disagree with that statement. With global prevalence set to double to 2.9 million cases a year by 2040, early detection of prostate cancer (PC) often leads to a favorable outcome, with many patients thankfully responding very well to treatment. However, RedHill says around 20% of men with prostate cancer will either not respond to the current standard of care androgen receptor signaling inhibitor therapies, or will become resistant to these drugs, and will advance to a point where current treatments offer no additional hope. Patients who develop what is known as metastatic castrate-resistant prostate cancer (mCRPC) and are not responsive to hormone therapy, are left with virtually no treatment options. Invariably, they will go on to die from their cancer, the company says. But potentially, there may be some hope thanks to a clinical collaboration, funded by Bayer AG (ETR: BAYN), a large global pharma company, and the Ramsay Hospital Foundation, between RedHill, Bayer and Australian cancer researchers. The collaboration will involve a study to test the potentially enhancing effect of RedHill’s treatment, opaganib, in combination with Bayer’s darolutamide, in overcoming resistance to androgen receptor pathway inhibition (ARPI) treatment. First approved in 2021, and now approved in more than 80 countries, Bayer’s darolutamide was the fastest -growing androgen receptor blocker in the U.S. and continues to enjoy a strong growth trajectory, with sales in 2024 almost doubling 2023’s numbers. With more positive clinical data unveiled last year, and the expectation of additional approvals in more markets and across more prostate cancer indications, Bayer expects sales of darolutamide to peak at around $3 billion a year – potentially making it one of the most successful drugs in the prostate cancer space. Treating Advanced Stage Prostate Cancer A major driver of prostate cancer is androgen receptor signaling, which is why using chemical castration or androgen deprivation therapy has become a standard care treatment. Unfortunately, patients with advanced PC, and in particular those who have already progressed to mCRPC, become or are resistant to it, RedHill reports. However, the company also notes that according to the results of laboratory studies involving leading ARPI therapy, darolutamide, there may be a way to boost sensitivity to therapy and potentially overcome resistance – with the addition of another drug, opaganib. Opaganib is RedHill’s first-in-class, novel and orally-administered selective inhibitor of sphingosine kinase-2 (SPHK2). Opaganib has shown anti-inflammatory, anti-cancer and antiviral activity, and its mechanism of action, being an intracellular sphingolipid pathway modifier with multiple cell-level functions, including potential inhibition of tumor growth, supports the hypothesis that it could boost the efficacy of darolutamide, the company says. Cancer cells can block a cell-level process called apoptosis (programmed cell death), preventing the body from getting rid of unneeded or abnormal/unhealthy cells – a critical weapon our bodies use in fighting the spread of cancer. RedHill says prior research has shown that opaganib enhances androgen receptor signaling inhibitor efficacy in vitro through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS) and may potentially provide the key to overcoming darolutamide resistance in men with mCRPC. The company says, it is opaganib’s potential ability to induce metabolic stress in tumor cells that may be at the heart of the hope this study could bring people with mCRPC. With the prevalence of prostate cancer set to double over the next 15 years and only a 28% five-year relative survival rate in people with stage 4 prostate cancer, there is a significant need for new approaches in treating mCRPC patients. Pinpointing Who Is Most Likely To Benefit Patients with a poor prognosis due to ARPI resistance are most likely to benefit from an opaganib/darolutamide combination treatment approach, and identifying these patients will be key, RedHill says. As such, another innovation, a companion lipid biomarker test called PCPro, will be used to identify the right patients as part of the study. “Men with mCRPC have few treatment options available to them, and those positive for the PCPro marker of ARPI-resistance seem to have a particularly poor prognosis,” said Dr. Mark Levitt, RedHill’s chief scientific officer. “If the addition of opaganib can reduce the resistance to darolutamide therapy, this would represent a significant breakthrough in improving the ability to manage advanced treatment-resistant mCRPC for improved outcomes.” Phase 2 Trial Launching Soon Supported by Bayer and the Ramsay Hospital Foundation, the potential effectiveness of the opaganib/darolutamide combination will be put to the test in an 80-patient phase 2 clinical trial, due to start shortly. The placebo-controlled, randomized phase 2 study will evaluate the effect of opaganib, in combination with Bayer’s darolutamide, in overcoming resistance to standard-of-care androgen receptor pathway inhibition (ARPI) treatment in men with mCRPC who have not already received the newer AR signaling inhibitors such as enzalutamide, apalutamide, darolutamide or abiraterone. A primary endpoint of improved 12-month radiographic progression-free survival (rPFS) will be the key assessment of success in the study, but several secondary and exploratory endpoints will also be evaluated, the company noted. “The approach of developing therapeutic combinations and the companion lipid biomarker, PCPro, in parallel, is unique in metabolic targeting in metastatic prostate cancer, and this exciting study may provide proof of concept by testing the ability of sphingosine kinase-2 (SPHK2) inhibitors, such as opaganib, to overcome resistance to ARPI treatment,” said Professor Lisa Horvath, world-renowned prostate cancer researcher and chief clinical officer and director of research at Chris O’Brien Lifehouse. Sydney’s Chris O’Brien Lifehouse is a not-for-profit, comprehensive cancer hospital, that also developed the concept of using a PCPro marker-directed opaganib/darolutamide combination approach. “Cancer cells may block apoptosis (programmed cell death), an important cell-level process designed to help the body get rid of unneeded or abnormal/unhealthy cells – critical in fighting the spread of cancer,” Horvath said. Trial Partners Pedigree Australia is a global leader in the field, and the driving force behind this collaboration is Horvath and her team from Chris O’Brien Lifehouse. The trial will be led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), a leading Cancer Cooperative Trials Group specializing in conducting studies for prostate, bladder, kidney, testicular and penile cancers. Prostate cancer diagnoses are expected to surge as the population around the world ages, and fighting this deadly disease just took on new urgency. If this combination of RedHill’s opaganib and darolutamide proves itself in this study, it may go on to play an important role in helping to improve the prospects for hundreds of thousands of men with advanced prostate cancer who currently have a very bleak outlook. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 05, 2025 08:35 AM Eastern Standard Time

Image

Calamos Strives To Offer Safer Path To Bitcoin Investment

Benzinga

By JE Insights, Benzinga Representing a fundamental shift in how people store and assess wealth, Bitcoin (CCC:BTC-USD) and the broader cryptocurrency ecosystem has upended the financial paradigm. More than fifteen years ago, when BTC made its public debut, hardly anyone knew anything about decentralized digital assets. Today, cryptos have become a cornerstone of innovation-centric portfolios, with financial services provider Calamos Investments aiming to offer a fresh rethink. It's no exaggeration to say that cryptos have reshaped the financial landscape. Last year, data from Bank of America Private Bank revealed that millennial investors aged 21 to 43 who have at least $3 million are taking an unconventional approach to the blockchain. Specifically, the average portfolio exposure to these financial instruments among self-identified conservative investors stands at a lofty 17%. Such normalization of risk flies in the face of traditional investment wisdom, where conservative exposure typically entails generous portions of stable assets like bonds and blue-chip dividend stocks. Given the anti-establishment nature of crypto investing, the literature of what is considered acceptable risk could fluctuate significantly in the future. Still, investors who partake in the crypto journey cannot overcome a simple fact: Bitcoin is prone to wild volatility. Current events alone make that clear; recently, the Federal Reserve elected to keep interest rates unchanged, snapping a streak of three consecutive rate cuts that began in September. At the same time, during a press conference, Federal Reserve chair Jerome Powell delivered bullish commentary on cryptos, giving praise for ongoing efforts to provide regulatory clarity for the blockchain ecosystem. With this relatively simple act, Bitcoin — which just a few days prior conspicuously slipped below the six-digit price threshold — screamed higher, reclaiming the $104,000 mark. That was just one incident. History is replete with examples of flash crashes and secular implosions that have both attracted people to, and repulsed others away from cryptocurrencies. Many are seeking an alternative mechanism to Bitcoin, one that buffs out its rough edges — a solution that Calamos’ hopes falls under its purview. Calamos ETF Products: Striving To Integrate Innovation With Familiarity Materializing concurrently with soaring interest in Bitcoin and other cryptos is the rise of the exchange-traded fund. Typically providing a basket of securities, ETFs have become attractive to some everyday investors for their simplicity and efficacy. The proof is in the numbers. According to Statista, the value of assets undergirding global ETFs landed at only $204.3 billion in 2003. Two decades later, this metric skyrocketed to over $11.5 trillion. Today, it’s not at all uncommon to see ETFs cover various sectors and even investment strategies. Some funds simply cover one security. Within this diverse arena stands Bitcoin ETFs — and to expectations, the category has enjoyed a lot of success. During the debut of the first BTC-focused funds, the financial vehicles saw tens of millions of shares (technically “units” of the fund) change hands. The combined trading volumes soared into the billions, demonstrating the popularity of virtual currencies. However, even on Wall Street proper, critics have noted that the journey within the ETF realm has been as volatile as the crypto market itself. What many investors have sought in response to these wild pricing dynamics is an alternative mechanism to Bitcoin — one that aligns with BTC’s growth potential while also providing the mitigatory frameworks common in advanced equity-trading strategies. That’s where Calamos may come in, with a portfolio of innovative products called the Calamos Protected Bitcoin ETF Suite. Earlier, the financial services provider generated waves by offering the Calamos Bitcoin Structured Alt Protection ETF. Listed on the Chicago Board Options Exchange (CBOE), the fund — which features the ticker symbol CBOJ — represents the world’s first 100% downside protected Bitcoin ETF. Thanks to a combination of government-backed bonds and financial derivatives, the actively managed CBOJ fund offers a regulated mechanism to access Bitcoin within a risk-controlled framework. Essentially, the management team overseeing CBOJ does the heavy lifting for investors, allowing them to ride Bitcoin’s gains while also potentially receiving the benefits of skilled evasive action during periods of volatility. Expanding The Suite: CBXJ And CBTJ Building on the foundation laid by CBOJ, Calamos is now expanding its Protected Bitcoin ETF Suite with two new funds: CBXJ and CBTJ. These ETFs introduce a tiered approach to Bitcoin investing, allowing market participants to choose the level of downside protection that aligns with their risk tolerance and financial objectives. At their core, CBXJ and CBTJ function similarly to CBOJ, using a structured mix of U.S. Treasuries and options on the CBOE Bitcoin US ETF Index to provide exposure to BTC while mitigating its volatility. However, unlike CBOJ’s 100% downside protection, these funds introduce calculated risk in exchange for higher upside potential. CBXJ provides 90% downside protection, meaning investors bear a maximum loss of 10% if Bitcoin declines during the one-year outcome period. In return for this slight exposure to risk, CBXJ offers a significantly higher initial upside cap rate of 29.15%, compared to CBOJ’s 11.65%. CBTJ offers 80% downside protection, meaning investors take on a maximum 20% loss but benefit from an even greater initial upside cap rate of 51.50%. All three ETFs will reset annually, with a new upside cap set for each outcome period, allowing investors to reassess their positions based on market conditions. This tiered structure provides flexibility. CBOJ is best suited for those prioritizing capital preservation, while CBXJ and CBTJ offer options for investors willing to accept some level of risk in exchange for higher returns. Rather than forcing a binary choice between Bitcoin’s volatility and complete safety, Calamos’ suite allows investors to customize their exposure to the asset’s potential without going all in. Tiered Risk Management Bitcoin remains one of the most disruptive forces in modern finance, but its volatility continues to be a roadblock for many investors. While traditional Bitcoin ETFs offer direct exposure to the asset, they typically do little to control the wild swings that have defined crypto markets. Calamos’ Protected Bitcoin ETF Suite aims to change the equation, offering investors a structured framework that tempers Bitcoin’s downside while preserving its upside potential. With CBOJ, CBXJ and CBTJ, Calamos introduces a tiered approach to risk management, allowing investors to choose the level of protection that fits their strategy. Whether it’s full capital preservation with CBOJ, moderate downside risk with CBXJ or higher upside exposure with CBTJ, these ETFs strive to bridge the gap between Bitcoin’s potential and the risk controls found in advanced equity strategies. As Bitcoin adoption continues to accelerate, products like these could play a role in mainstreaming crypto investments. Instead of forcing investors to take an all-or-nothing bet on Bitcoin, Calamos aims to provide a middle ground — an entry point into the digital asset revolution without as much volatility. Featured photo by Satheesh Sankaran from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Before investing, carefully consider the fund’s investment objectives, risks, charges and expenses. Please see the prospectus and summary prospectus containing this and other information which can be obtained by calling 1-866-363-9219. Read it carefully before investing. ©2025 Calamos Investments LLC. All Rights Reserved. Calamos®, Calamos Investments® and Investment strategies for your serious money® are regis- tered trademarks of Calamos Investments LLC. Calamos Investments LLC, referred to herein as Calamos Investments®, is a financial services company offering such services through its subsidiaries: Calamos Advisors LLC, Calamos Wealth Management LLC, Calamos Finan- cial Services LLC and Calamos Antetokounmpo Asset Management LLC. Cap rate and ranges are shown gross of management fees. *Cap rates and ranges are shown gross of management fees. Initial cap rates shown are calculated on the business day prior to fund launch. Cap ranges—Ranges are based on multiple estimated cap rates obtained from 1/2/25 - 1/17/25, based on market conditions during the sample period, and are subject to change. The actual cap rates may be different based on market events The information in each fund’s prospectus and statement of addition- al information) is not complete and may be changed. We may not sell the securities of any fund until such fund’s registration statement filed with the Securities and Exchange Commission is effective. Each fund’s prospectus and statement of additional information is not an offer to sell such fund’s securities and is not soliciting an offer to buy such fund’s securities in any state where the offer or sale is not permitted. Each of CBOJ, CBOA, CBOY and CBOO seeks to provide investment re- sults that, before taking fees and expenses into account, track the positive price return of the CME CF Bitcoin Reference Rate – New York Variant (“BRRNY”) (“Spot bitcoin”) up to a predetermined upside cap (the “Cap”) while seeking to protect against 100% of losses (before fees and expenses) of (i) Spot bitcoin or (ii) one or more of the Underlying ETPs and/or Bitcoin Indexes, in each case, over a period of approximately one (1) year (the “100% Protection 1 Year Outcome Period”). Each of CBSJ and CBSY seeks to provide investment results that, before taking fees and expenses into account, track the positive price return of Spot bitcoin up to a Cap while seeking to protect against 100% of Spot bitcoin losses (before fees and expenses) over a period of approximately six months. Each of CBXJ, CBXA, CBXY and CBXO seeks to provide investment results that, before taking fees and expenses into account, track the positive price return of Spot bitcoin up to a Cap while seeking to provide a floor with protection to a maximum loss of 10% of the negative price return of Spot bitcoin (before fees and expenses) over a period of approximately one year (the “90% Protection Outcome Period”). Each of CBTJ, CBTA, CBTY and CBTO seeks to provide investment results that, before taking fees and expenses into account, track the positive price return of Spot bitcoin up to a Cap while seeking to provide a floor with protection to a maximum loss of 20% of the negative price return of Spot bitcoin (before fees and expenses) over a period of approximately one year (the “80% Protection Outcome Period” and collectively with the 100% Protection 1 Year Outcome Period, and 90% Protection Outcome Period, each an “Outcome Period”). The Funds will not invest directly in bitcoin. Instead, the Funds seeks to provide investment results that, before taking fees and expenses into ac- count, track the positive price return of Spot bitcoin by investing in options that reference the price performance of either (i) one or more underlying exchange-traded products (“Underlying ETPs”) which, in turn, own bitcoin or (ii) one or more indexes that are designed to track the price of bitcoin (“Bitcoin Index”). A Fund’s Target Outcome may not be achieved, and investors may lose some or all of their money. Each Fund is designed to achieve the Target Outcome only if an investor buys on the first day of the Outcome Period and holds the Fund until the end of the Outcome Period. While each Fund seeks to provide a specified percentage of protection against loss- es experienced by the price of Spot bitcoin for shareholders who hold Fund Shares for an entire Outcome Period, there is no guarantee it will successfully do so. If a Fund’s NAV has increased significantly, a share- holder that purchases Fund Shares after the first day of an Outcome Period could lose their entire investment. An investment in a Fund is only appropriate for shareholders willing to bear those losses. There is no guarantee the Capital Protection or Floor, as applicable, and Cap will be successful and a shareholder investing at the beginning of an Outcome Period could also lose their entire investment. An investment in a Fund is subject to risks, and you could lose money on your investment in a Fund. There can be no assurance that a Fund will achieve its investment objective. Your investment in a Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation (FDIC) or any other government agency. The risks associated with an investment in a Fund can increase during times of significant market volatility. Each Fund also has specific principal risks, which are described below. More detailed information regarding these risks can be found in each Fund’s prospectus. Digital Assets Risk: The bitcoin network was first launched in 2009 and bitcoins were the first cryptographic digital assets created to gain global adoption and critical mass. Although the bitcoin network is the most established digital asset network, the bitcoin network and other cryptographic and algorithmic protocols governing the issuance of digital assets represent a new and rapidly evolving industry that is subject to a variety of factors that are difficult to evaluate. Moreover, because digital assets, including bitcoin, have been in existence for a short period of time and are continuing to develop, there may be additional risks in the future that are impossible to predict as of the date of this prospectus. Digital assets represent a new and rapidly evolving industry, and the value of the Underlying ETPs’ shares depends on the acceptance of bitcoin. The realization of one or more of the following risks could materially adversely affect the value of the Underlying ETPs’ shares. Investing involves risks. Loss of principal is possible. The Funds face numerous market trading risks, including authorized participation concentration risk, underlying ETP risk, cap change risk, capital protection risk or floor risk, as applicable, capped upside risk, cash holdings risk, concentration risk, clearing member default risk, correlation risk, costs of buying and selling fund shares, counterparty risk, derivatives risk, equity securities risk, FLEX options risk, interest rate risk, investment in a subsidiary, investment timing risk, liquidity risk, management risk, market maker risk, market risk, new fund risk, non-diversification risk, options risk, OTC options risk, position limits risk, premium-discount risk, secondary market trading risk, sector risk, tax risk, trading issues risk, U.S. Government security risk, U.S. Treasury risk, and valuation risk. For a detailed list of fund risks see the prospectus. With respect to each of CBOJ, CBOA, CBOY and CBOO, 100% capital protection is over a one-year period before fees and expenses. With respect to each of each of CBSJ and CBSY, 100% capital protection is over a six month period before fees and expenses. All caps are pre-determined. Cap Rate – Maximum percentage return an investor can achieve from an investment in the Fund if held over the Outcome Period. Protection Level – Amount of protection the Fund is designed to achieve over the Days Remaining. Outcome Period – Number of days in the Outcome Period Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 05, 2025 08:35 AM Eastern Standard Time

Image

The 3 Top Crypto Coins To Buy in the Dip: Cutoshi (CUTO) Set To Mint New Millionaires

Cutoshi

As the bear trend continues to bite harder, stats show that the crypto market has officially slipped into the fear index for the first time since October. Meanwhile, investors can still position for significant ROIs by investing in the right crypto assets. For instance, the Cutoshi presale project is seeing an influx of traders, given its exponential growth potential, strong utility, and effectiveness as a hedge against the current bear trend. The other two crypto assets include Solana and Ethereum, two tokens heavily backed by analysts to bull soon. Solana (SOL) Regains Support Above $200, Displays Buy Signal Like most crypto assets in the past week, the Solana token has witnessed a sharp correction in the past few days. According to CoinMarketCap, Solana's price has lost 10% in value within the last week. The token's market volume has also suffered a loss. Nonetheless, Solana has maintained support above the $200 mark with a possible breakout. According to Ali Martinez Solana's price chart analysis, the TD sequential indicator of the SOL token has created a potential buy signal. This means that the Solana crypto could be on the edge of a bullish breakout, which might see the altcoin price retest the $250 mark. As such, the dip opens a buy zone opportunity to invest in the altcoin. Meanwhile, Solana retains its position as 5th most valuable crypto asset by market capitalization, as per stats. Only four assets in Bitcoin, Ethereum, XRP and USDT are more valued than Solana in the crypto industry. Given the growing adoption of the Solana blockchain in building various projects, the SOL price might set new records in 2025. Ethereum (ETH) Tipped to Go Parabolic As it Displays Key Indicator Ethereum has been backed to reach the $7,000 mark by analyst Poseidon in an X post. According to the tweet, the Ethereum token has recorded a double bottom formation, a pattern that usually precedes a significant uptrend. Similarly, another analyst, Ted Pillows, has listed why he is convinced about Ethereum. Some of the points he highlighted in his post include Ethereum's commodity status and spot ETF support, as well as over 2 million Ethereum tokens bought by Trump, among others. Recent data from on-chain market tracker Lookonchain showed that Trump's World Liberty bought another 1,826ETH ($5M) as Eric Trump suggested that traders should buy Ethereum. For the time being, Ethereum's price trajectory has been bearish as per CoinMarketCap. With stats showing a 21% value decline in the past month and another 11% within the past week, Ethereum has effectively fallen below the $3,000 mark and will need significant momentum to rebound. Best Time to Buy the Presale of the Luckiest Meme Coin: Cutoshi (CUTO) Even as a significant number of assets in the crypto market are liquidating, Cutoshi (CUTO) has maintained a surging trajectory with more investors accumulating the token. So far, millions of CUTO tokens have been sold with close to $2 million raised in cryptocurrency ICO funding. Early investors' ROI has jumped to over 106% even as the presale is just in stage 4. Based on the presale’s trajectory, another 500x growth is expected to happen before launch, making it one of the best crypto coins to buy. For context, Cutoshi is a DeFi hub and educational platform inspired by the traditional Chinese Lucky Cat and the vision of Satoshi Nakamoto. Cutoshi aims to open up the blockchain for the benefit of the entire masses and not just the elite few. Cutoshi's core use cases include a multi-chain DEX exchange, yield farming infrastructure, DeFi academy, and more. All these contribute to ensuring the decentralization purpose of DeFi against the move for regulation by key actors like the government and BlackRock. At Cutoshi, decentralization and financial freedom are the main focus. No doubt it is seen as a tribute to decentralized finance while on a mission to bring DeFi closer to the masses. The native token, CUTO, serves as a means of cashback and promotional offers in the ecosystem. At just $0.031, investors can accumulate the token and position themselves for potential exponential growth. Best Crypto Investment Alternative in Q1 Since the bear trend started, Solana and Ethereum have shown great bullish promise. However, only Cutoshi has maintained a rallying trajectory. While Cutoshi may not be a giant in the crypto industry yet, it harbors a higher growth percentage than tokens like Solana and Ethereum at the moment. Given its low price entry advantage, 500x growth projection, and strong utility, investing in Cutoshi could turn an average investor into a millionaire in 2025, just as Pepe did two years ago. For more information on the Cutoshi (CUTO) Presale: https://cutoshi.com/ Join and become a community member: https://twitter.com/CutoshiToken https://t.me/cutoshicommunity Cutoshi is a revolutionary meme coin inspired by the Chinese Lucky Cat and Satoshi Nakamoto’s teachings. It’s based on decentralization, privacy, and monetary freedom, embodying the blockchain's original purpose and ethos. Cutoshi has a vision - to introduce more people to cryptocurrencies and bring financial freedom to all who want it. Contact Details Cutoshi Camila Perez support@cutoshi.com Company Website https://cutoshi.com/

February 05, 2025 08:16 AM Eastern Standard Time

Image

Biotech Investing: How PRVs Can Unlock Major Opportunities

Raz

In the world of biotechnology investing, companies often struggle to bring new drugs to market. Developing treatments for rare diseases can be incredibly expensive, and because these conditions affect relatively few patients, the financial payoff isn't always clear. To help incentivize drugmakers, the U.S. government created the Priority Review Voucher (PRV) program in 2007. PRVs act as a powerful tool that can significantly speed up the FDA approval process, making them a highly valuable asset—especially to major pharmaceutical companies. A PRV is awarded when a company gains approval for a drug that treats a rare pediatric disease (RPD), a tropical disease, or serves as a medical countermeasure for serious public health threats. Normally, FDA drug approvals take around 10 months, but using a PRV shortens that timeline to just six months. This four-month head start can be a game-changer, allowing companies to get a competitive edge or generate extra sales from blockbuster drugs. Since these vouchers don’t expire and can be freely bought and sold, they often end up in the hands of big pharmaceutical companies willing to pay top dollar for the advantage. PRV prices have historically hovered around $100 million, but with uncertainty surrounding the renewal of the rare pediatric disease PRV program, recent sales have surged past $150 million. If the program isn’t renewed, PRVs could become even scarcer, potentially driving prices even higher. Big pharma companies are fiercely competing for these vouchers, particularly in lucrative fields like obesity treatments, where shaving months off a drug’s approval timeline could mean capturing billions in market share. For small biotech companies, receiving a PRV can be a major financial boost. Take Day One Biopharmaceuticals (NASDAQ: DAWN) as an example. The company was awarded a PRV after its pediatric cancer drug, OJEMDA (tovorafenib), received FDA approval. Rather than using the voucher itself, Day One sold it for $108 million, securing much-needed funding without diluting shareholder value. This kind of transaction highlights why PRVs can be a game-changer for biotech firms—providing an immediate cash infusion that can support further drug development. With PRVs becoming an increasingly hot commodity, investors should keep an eye on biotech companies with potential voucher-earning drugs in development. With PRVs becoming increasingly valuable, several biotech companies could be next in line to benefit. Let’s take a look at three stocks with potential PRVs on the horizon. OS Therapies: OS Therapies (NYSE-A: OSTX) is emerging as a strong contender for a Priority Review Voucher (PRV), a potential game-changer for the company. The company is developing OST-HER2, an immunotherapy designed to prevent the spread of osteosarcoma (OS), a rare and aggressive bone cancer that primarily affects children and young adults. Because OS Therapies holds a Rare Pediatric Disease Designation (RPDD) from the FDA, an approval for OST-HER2 would make it eligible for a PRV—potentially bringing in around $150 million in non-dilutive funding. For a small biotech company, this is a game-changing opportunity. "The data we generated in our Phase 2b trial with OST-HER2 provides the first glimmer of hope in over 40 years that a paradigm shift could radically change the course of this deadly disease," said CEO Paul Romness. If OS Therapies secures FDA approval, not only would it mark a major breakthrough for osteosarcoma treatment, but the PRV could also provide the financial runway needed for future expansion. OS Therapies has already hit a key milestone, achieving the primary endpoint in its Phase 2b trial for OST-HER2. The treatment demonstrated a 33% Event-Free Survival (EFS) rate at 12 months, compared to just 20% in historical controls. Even more compelling, 91% of patients treated with OST-HER2 were alive at the one-year mark, versus 80% in the control group. These results indicate a significant improvement over existing treatment options, which have remained largely unchanged for decades. With these promising results in hand, OS Therapies plans to file for FDA approval (Biologics Licensing Application, or BLA) in late 2025, with potential approval by mid-2026. If successful, the company would receive a PRV just before the program sunsets, making it one of the last biotechs to benefit from this lucrative incentive. Financial Stability and Growth Potential Despite being a small-cap biotech, OS Therapies has positioned itself well financially. Over the past six months, the company raised $13.1 million through an IPO and a subsequent private placement. These funds are earmarked for final clinical trial payments, commercial manufacturing, and regulatory expenses—all crucial steps toward bringing OST-HER2 to market. Moreover, OS Therapies recently acquired key clinical assets from Ayala, including two additional Listeria-based immunotherapy candidates for lung and prostate cancer. This acquisition not only expands the company’s pipeline but also significantly reduces future cash obligations, improving long-term financial prospects. The Bigger Picture Beyond osteosarcoma, OST-HER2 has potential applications in other HER2-positive cancers, including breast cancer and canine osteosarcoma, where it has already received conditional approval from the U.S. Department of Agriculture. Additionally, the company is advancing its tunable Antibody Drug Conjugate (tADC) platform, a next-generation cancer therapy designed to improve targeted drug delivery. With multiple clinical programs, a solid financial strategy, and a real chance at securing a PRV, OS Therapies stands out as a compelling investment opportunity in biotech. If OST-HER2 gains FDA approval, the PRV could provide a significant financial boost—offering the company valuable resources for further development and creating substantial upside potential for investors. SpringWorks Therapeutics: SpringWorks Therapeutics (Nasdaq: SWTX) is a biotech company focused on developing treatments for severe rare diseases and cancer. Its first FDA-approved drug, OGSIVEO® (nirogacestat), treats desmoid tumors, but the company’s next major opportunity lies with mirdametinib—a drug currently in development for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare condition that causes tumors to form along nerves. In the ReNeu trial, mirdametinib showed impressive results in both adults and children, reducing tumor size and improving pain and quality of life. Because of these promising outcomes, the FDA has granted Priority Review status to the drug, with a decision expected by February 28, 2025. If mirdametinib is approved, SpringWorks could earn a Priority Review Voucher (PRV), which would be a highly valuable asset for the company. A PRV allows for a faster approval process, providing a significant advantage for drugmakers. The company could choose to sell the PRV for a substantial financial boost, potentially funding future drug development or pipeline expansion without diluting shareholder value. With SpringWorks poised to potentially earn a PRV through mirdametinib, 2025 could be a pivotal year for the company, positioning it as a leader in rare disease treatments. Investors should keep a close eye on SpringWorks as it works toward FDA approval for mirdametinib and the possible PRV windfall. PTC Therapeutics PTC Therapeutics, Inc. (NASDAQ: PTCT) is a biopharmaceutical company dedicated to developing innovative treatments for rare diseases. The company has two important drugs that could earn PRVs in the near future, each representing a valuable opportunity for investors. First, vatiquinone, a drug for Friedreich ataxia (FA)—a rare, progressive disease that affects the nervous system—has been submitted for FDA approval. The company believes this drug could fill a big gap in treatment for both children and adults with FA, as there are very few options available right now. Vatiquinone has shown strong results in clinical trials, with evidence of slowing disease progression and improving quality of life. If approved, it could earn PTC a PRV, which could then be sold for a significant financial boost. The second drug, Sepiapterin, is being developed for phenylketonuria (PKU), a rare metabolic disorder that can cause serious developmental issues. PTC recently submitted Sepiapterin for FDA approval, based on promising trial results showing it can help patients manage the disease and even reduce their reliance on strict diets. If this drug gets FDA approval, it could also bring in a PRV for PTC, providing an additional source of funding. With two drugs in the pipeline that have the potential to earn PRVs, PTC Therapeutics is an exciting company to watch. These PRVs could provide significant financial support, helping the company continue its important work in rare disease treatments. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

February 05, 2025 07:00 AM Eastern Standard Time

News Release

Financial Gravity Companies, Inc. Files FY2024 Year-End Report, Celebrates Sustained Profitability and Strategic Growth

Financial Gravity Companies, Inc.

Financial Gravity Companies, Inc. (OTC: FGCO) proudly announces the filing of its report for the first quarter of fiscal year 2025. The results underscore a continuation of our progress on profitability, growth, and our offerings for financial advisors and their clients. Financial Gravity remains focused on its mission to provide exceptional financial services to its clients through its proprietary Multi-Family Office model that provides integrated solutions that combine wealth management, tax planning, tax compliance and return preparation services, and risk mitigation. Financial Gravity will continue to focus on differentiating the company in the financial services industry by providing coordinated financial services in a one-stop shop and driving long-term value for advisors and their clients. Key financial and operational highlights include: Profitability For Fiscal Quarter: The company achieved a net income of $46,000 for Q1 2025. Revenue Growth: Our operating showed an increase in revenue year over year of about $200,000. Strategic Investments in Offerings: Financial Gravity invested in its platform to make it more compelling for the advisors it recruits and their clients. Enhancements include proprietary content, the use of artificial intelligence to drive the integration of more services and automation features, and technology upgrades to enrich the advisor and client experience. Scott Winters, CEO of Financial Gravity, stated: "The first quarter of FY2025 marked a continuation of our improvement in net income over the first quarter of last fiscal year. Our improvement of systems will help ensure that we continue to deliver exceptional value to advisors and their clients while positioning the company for sustained growth. We are committed to advancing our mission to democratize the delivery of integrated financial services to mass affluent clients through our proprietary Multi-Family Office experience." For additional details, please refer to the full year-end report available on the OTC Markets platform. About Financial Gravity Companies, Inc. Financial Gravity Companies Inc., along with its subsidiary companies, provides investment and tax professionals with a turnkey family office charter. We help tax professionals evolve from the commoditized business of tax compliance to a Family Office Director that runs and manages their own multi-family office. Family Office Directors are able to leverage the Financial Gravity systems, technology, proprietary resources, and deep domain expertise to bring an elevated and holistic financial service experience to their clients that spans proactive tax planning, retirement and estate planning, wealth management, and risk mitigation. For more information about Financial Gravity Companies, Inc., please visit https://financialgravity.com. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert, or change any of them and could cause actual outcomes and results to differ materially from the current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Financial Gravity's business, and Financial Gravity undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Contact Details Financial Gravity Companies, Inc. Scott Winters +1 800-588-3893 scott.winters@financialgravity.com Company Website https://financialgravity.com/

February 05, 2025 06:00 AM Eastern Standard Time

Crypto Market Crash: How Cutoshi Is Saving Crypto Investors From The Market Decline Affecting Cardano and XRP

Cutoshi

It is no longer news that the market-wide bearish trend has affected most crypto assets in recent days. Amid the frenzy of bearish signals, traders have found a foolproof investment alternative to save their portfolio through the Cutoshi project. Cutoshi (CUTO) displays remarkable utility depth that has made it a standout DeFi project to buy in Q1. Meanwhile, there's substantial uncertainty surrounding the short-term future of some popular top crypto coins like Cardano and XRP as they continue to record declining price value. Massive Bearish Hit for Cardano as it Loses 21% Cardano (ADA) is one of the altcoins affected by the market-wide bear trend. According to stats, the Cardano token lost over 21% within the past week. Zooming out, the token has lost 30% in value over the past month, further depleting the token's chance of breaking into the $1 mark. The token has declined to a new low of $0.75 for the first time since last November. Meanwhile, few crypto analysts, such as Sebastian on X, are confident that Cardano's price will break its bearish trajectory to regain support toward the $0.90 mark. Within the month, Cardano's market cap valuation has lost over $12 billion as the average daily market volume has declined. It is no wonder that investors are buying the Cutoshi presale to cushion the bearish impact on Cardano. Analyst Projects a Long Entry Opportunity for XRP Amid Bear Trend While the XRP token was among the highest gainers within the last two months, the recent bear trend across the crypto market has seen the token decline in value. According to stats from CoinMarketCap, XRP's price could drop below the $2.5 critical support zone having declined by over 16% in value within the past week. However, the XRP price chart of the past 24 hours looks to have broken the bear trend as the market cap continues to grow. Notably, crypto analyst VipRoseTr sees the current price value as a good entry point ahead of a potential rally for the token. According to the X post from VipRoseTr, the XRP crypto price is “approaching a key demand zone,“ offering an opportunity to buy and position the token for growth. The analyst set an ultimate price target of $4.33 for XRP. With news of Japanese banks adopting XRP in the coming weeks and the high possibility of XRP ETF in 2025, Ripple remains one of the top altcoins to watch in 2025. Cutoshi (CUTO) Maintains Surging Presale Momentum, Sets Sight on 500x Growth As the market trajectory of crypto assets plunges to a new low, Cutoshi (CUTO) maintains its high-flying momentum in presale. Thousands of new traders are joining the project thanks to its revolutionary DeFi solution and diverse use cases. So far, buyers of the Cutoshi presale have recorded significant ROIs, given the 106% value growth from the presale. Notably, an additional growth projection of over 500x is expected of the Cutoshi presale before launch. As such, it makes Cutoshi one of the best cryptocurrencies to invest in Q1 of 2025. The massive growth projection of Cutoshi is tied to its revolutionary DeFi solutions and how it creates paths to financial freedom for all. With increasing interest in regulating the blockchain by the government and BlackRock, Cutoshi stands firm in championing the freedom of decentralization for all. Through utilities such as the Cutoshi DEX exchange, yield farming infrastructure and academy, the project will bring all the benefits of DeFi to the masses and not just the elite few. That is why insightful traders are already buying out the project's presale ahead of massive rallies. At just $0.031, now is the best time to accumulate the CUTO token at this nascent stage. The Cutoshi token has a strict supply of 440M, of which 55% is mapped out for presale and 7% for burning events. Given the deflationary mechanism and low supply, there are high chances of token scarcity soon, which will drive the price up. Best Crypto Token to Buy Amid the Bear Market Sentiment With the bear wave affecting top crypto coins like Cardano and XRP, one of the best investment options is to buy presale tokens like Cutoshi. The Cutoshi presale hedges investors against the bear trend while also positioning them for the massive growth potential. Cutoshi's quality utilities, low price point, and exponential ROI potential make it one of the best crypto assets to invest in Q1. For more information on the Cutoshi (CUTO) Presale: https://cutoshi.com/ Join and become a community member: https://twitter.com/CutoshiToken https://t.me/cutoshi Cutoshi is a revolutionary meme coin inspired by the Chinese Lucky Cat and Satoshi Nakamoto’s teachings. It’s based on decentralization, privacy, and monetary freedom, embodying the blockchain's original purpose and ethos. Cutoshi has a vision - to introduce more people to cryptocurrencies and bring financial freedom to all who want it. The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Custoshi. Contact Details Cutoshi Camila Perez support@cutoshi.com Company Website https://cutoshi.com/

February 05, 2025 05:34 AM Eastern Standard Time

Image

ASSOCIATION OF PICKLEBALL PLAYERS AND HUMANA ANNOUNCE MULTI-YEAR PARTNERSHIP EXTENSION

Association of Pickleball Players

The Association of Pickleball Players (APP) has announced a multi-year extension of its partnership with leading health and well-being company Humana Inc. as the official healthcare partner of the APP Tour. Humana has joined forces with the world’s first pickleball tour on a variety of initiatives, including the return of the season-long Humana Cup pro player competition and title sponsorship of the season-opening 2025 Humana APP Fort Lauderdale Open. “We are proud to see our partnership continue to grow with Humana, who are steadfast supporters of pickleball and the sport’s role in a healthy lifestyle,” said APP Chief Revenue Officer Ryan McSpadden. “Together, we’ll continue to share the benefits of pickleball for staying active and maintaining good health, both on and off the court.” "This exciting opportunity not only builds upon our already successful partnership with APP but also our strong commitment to putting health first for our members and the communities we serve," said Humana Chief Marketing Officer Jennifer Ilecki. “Supporting the APP – along with its groundbreaking initiatives and competitions – showcases the importance of staying active for both physical and mental fitness. Whether you are a professional player, new to the sport, or prefer to come out and watch or volunteer at a tournament, pickleball offers something for everyone.” First introduced in 2024, the Humana Cup is the first-of-its-kind season-long team competition format exclusively for professional pickleball players in two divisions – Champions (50 and older) and Masters (60 and older). The 2025 Humana Cup will take place over seven APP Tour events throughout the country, with season-long prize money, and the title of Humana Cup champions up for grabs. Ten total Humana Cup teams competed in 2024, with full results available at theapp.global. “The Humana Cup showcases some of the best pickleball players in the world and is a truly unique part of the APP Tour,” added APP Founder Ken Herrmann. “The competition brings intensity, camaraderie, and a level excitement you won’t find anywhere else at this level and with such an important group of players. May the best team win!” The Humana Cup is scheduled to take place at the following events in 2025: APP Vlasic Classic – Daytona Beach | Feb. 4-9 APP Sacramento Open ^ | Feb. 25 – Mar. 2 APP Fort Lauderdale Open | Apr. 1-6 APP New York City Open ^ | May 20-25 APP Newport Beach Open | July 1-6 APP Dallas Open % | Oct. 8-12 APP Boca Raton Open ^ | Nov. 4-9 APP International Championships (Fort Lauderdale) | Dec. 9-14 ^ Champions (50+) division only % Masters (60+) division only *All dates and locations subject to change The 2025 Humana Cup competition will feature six Champions pro teams of 14 players—seven men and seven women—and six Masters pro teams of 10 players—five men and five women—totaling 84 Champions players and 60 Masters players. Players will be drafted by team captains to their respective teams in the coming weeks. The teams will go head-to-head in men’s doubles, women’s doubles and mixed doubles in a round-robin format for the majority of its 2025 events leading up to a semifinal weekend. The 2025 Humana Cup season will then conclude with a final weekend held at the APP’s global headquarters at The Fort in Fort Lauderdale to determine the overall Humana Cup team champions. The 2025 APP Tour season began with the Humana APP Fort Lauderdale Open, held Jan. 15-19 at The Fort. Players and spectators were part of pickleball history with a first look at the world-class venue, which boasts 43 courts and the world’s first pickleball stadium. The Humana brand was immersed prominently within the event, and will continue at all APP Tour events throughout 2025, with the Humana Backcourt recovery lounge, the Humana Human Care Spotlight featured on the APP’s national television broadcasts, signage and more. Player registration for 2025 APP Tour events is now live via theapp.global. The pickleball community can stay in the know on the latest APP updates by following the APP’s Instagram, X, Threads, TikTok, Facebook and LinkedIn channels. # # # APP Media Contact: Daniel Sagerman, dsagerman@theapp.global or 847-800-8182 Humana Media Contact: Kelli LeGaspi, klegaspi1@humana.com About the APP: The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be featured on nationally televised broadcasts on CBS Sports, ESPN and FOX Sports. Since its launch in 2019, the APP has operated the first and only pro and amateur pickleball tour fully and officially sanctioned by USA Pickleball. The APP opened its official headquarters and player development center in January 2025 at The Fort in Fort Lauderdale, Fla., while its corporate offices continue to be located in Chicago. The APP Tour’s 2025 schedule will feature the most robust pickleball showcase across pro and amateur competitions accompanied by youth development programs, grassroots charity initiatives and international partnerships to continue to grow the game. Schedules, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. About Humana: Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com. The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be featured on nationally televised broadcasts on CBS Sports, ESPN and FOX Sports. Since its launch in 2019, the APP has operated the first and only pro and amateur pickleball tour fully and officially sanctioned by USA Pickleball. The APP opened its official headquarters and player development center in January 2025 at The Fort in Fort Lauderdale, Fla., while its corporate offices continue to be located in Chicago. The APP Tour’s 2025 schedule will feature the most robust pickleball showcase across pro and amateur competitions accompanied by youth development programs, grassroots charity initiatives and international partnerships to continue to grow the game. Schedules, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. Contact Details Association of Pickleball Players Daniel Sagerman +1 847-800-8182 dsagerman@theapp.global Humana Kelli LeGaspi klegaspi1@humana.com

February 04, 2025 12:46 PM Eastern Standard Time

ALTITUDE SPORTS RETURNS TO XFINITY!

Comcast Mountain West

Kroenke Sports & Entertainment (KSE), owner of the Altitude Sports television network, and Comcast announced today that Altitude Sports has returned to Xfinity TV customers throughout Colorado and New Mexico, plus parts of Arizona and Kansas. Xfinity customers will now have access to all live game broadcasts of the KSE-owned Denver Nuggets (NBA) and Colorado Avalanche (NHL). “We are thrilled to once again make Denver Nuggets and Colorado Avalanche games available on Comcast and Xfinity platforms in Colorado and the surrounding region,” said KSE Vice Chairman Josh Kroenke. “This is the best possible outcome for Nuggets Nation and Avs Faithful, who now have a straightforward way to see every game on one service.” Where available, Altitude Sports will be accessible through multiple platforms, providing Xfinity customers with options for how to watch and subscribe to the network, whether on television, online, or through their mobile device. Beginning today, Altitude is on Xfinity channel 1250 in the Denver market as part of the Xfinity More Sports and Entertainment (MSE) video package, an add-on that can be purchased by subscribers to the Xfinity Sports & News, Popular TV, or Ultimate TV video services. The price for MSE on television will be adjusted to $15.95, effective April 8. To add the MSE package to existing Xfinity service, click here. To sign up for new Xfinity service, click here. Current subscribers to the MSE package in the territory will see the Altitude network in their channel lineup today Xfinity internet-only customers also will be able to subscribe to live-game streaming via the Altitude+ app for $19.95 per month. “Xfinity delivers the sports and entertainment customers love,” said J.D. Keller, Senior Vice President of Comcast’s Mountain West Region. “We’re excited to give fans more ways to watch the recent world-champion Avalanche and Nuggets through this new agreement with Altitude.” The channel lineup for Popular TV and Ultimate TV packages include the national networks that carry designated Nuggets and Avalanche games – ABC, ESPN, and TNT – making every game available on one service. “The real winners today are the fans,” said Mayor Mike Johnston. “In 20 years we’ll tell our children and grandchildren what it was like to watch Nathan MacKinnonand Nikola Jokić in theirprimes. This agreement gives fans more options on how to easily access games and ensures they won’t miss a second of the action. I’m thankful that Altitude and Comcast came to the table and worked together to close this deal. Their teamwork will benefit the fans, the players, and the city.” Altitude Sports will remain available on all of its other current carriers. A series of free over-the-air broadcasts of Nuggets and Avalanche games on 9NEWS and My20 are not impacted by the Comcast agreement and will continue to be shown on all Xfinity plans with local channels. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company that connects people to moments that matter. We are principally focused on broadband, aggregation, and streaming with over 56 million customer relationships across the United States and Europe. We deliver broadband, wireless, and video through our Xfinity, Comcast Business, and Sky brands; create, distribute, and stream leading entertainment, sports, and news through Universal Filmed Entertainment Group, Universal Studio Group, Sky Studios, the NBC and Telemundo broadcast networks, multiple cable networks, Peacock, NBCUniversal News Group, NBC Sports, Sky News, and Sky Sports; and provide memorable experiences at Universal Parks and Resorts in the United States and Asia. Visit www.comcastcorporation.com for more information. About Kroenke Sports & Entertainmen t Denver-based Kroenke Sports & Entertainment (KSE) is one of the world's leading ownership, entertainment, and management groups. KSE's portfolio of professional sports teams and venues include Arsenal F.C. (EPL), Los Angeles Rams (NFL), Denver Nuggets (NBA), Colorado Avalanche (NHL), Colorado Rapids (MLS), Colorado Mammoth (NLL), SoFi Stadium, Emirates Stadium, Ball Arena, DICK's Sporting Goods Park, and the Historic Paramount Theatre. Additional properties under KSE'ss umbrella include Altitude Sports & Entertainment, a 24-hour regional television network; Altitude+, the direct-to-consumer streaming service; KSE Radio, which includes Altitude Sports Radio 92.5 FM, MIX 100, KOOL, and Altitude Sports Radio 950 AM; and Outdoor Sportsman Group, the largest media company devoted to outdoor sports. About Altitude Sports Seen in a nine-state territory, Altitude Sports is the television network of the Denver Nuggets, Colorado Avalanche, and Colorado Mammoth. Altitude Sports broadcasts University of Denver sports (including hockey, basketball, soccer, volleyball, gymnastics, and lacrosse), the Air Force Academy (football, basketball, and hockey), as well as other local and regional sports, entertainment, and public service programming. A full list of Altitude Sports programming and other information can be found at www.altitudesports.com. Contact Details Comcast Leslie Oliver +1 303-810-6326 Leslie_Oliver@comcast.com KSE Jim Mulvihill +1 720-385-9149 Jim.Mulvihill@TeamKSE.com Company Website https://colorado.comcast.com

February 04, 2025 10:30 AM Mountain Standard Time

All Industries

The Bermuda Business Development Agency (BDA) Enters New Era as Investment Promotion Agency and Appoints Managing Director

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance

Calamos Strives To Offer Safer Path To Bitcoin Investment

The 3 Top Crypto Coins To Buy in the Dip: Cutoshi (CUTO) Set To Mint New Millionaires

Biotech Investing: How PRVs Can Unlock Major Opportunities

Financial Gravity Companies, Inc. Files FY2024 Year-End Report, Celebrates Sustained Profitability and Strategic Growth

Crypto Market Crash: How Cutoshi Is Saving Crypto Investors From The Market Decline Affecting Cardano and XRP

ASSOCIATION OF PICKLEBALL PLAYERS AND HUMANA ANNOUNCE MULTI-YEAR PARTNERSHIP EXTENSION

ALTITUDE SPORTS RETURNS TO XFINITY!